Leveraging the immune system to fight cancer – Biotech’s future

submitted by: nsf

Inventors are using small-scale biology and engineering to find ways to use the body’s natural defenses to effectively treat cancer. NSF-funded small business GigaGen uses microfluidics, bioinformatics and genome sequencing to look for antibodies that may be good candidates for new therapies. GigaGen’s David Johnson explained how at the 2014 BIO International Convention.

Monitoring multiple biomarkers at once – Biotech’s future

submitted by: nsf

NSF-funded small business Applied Biosensors has created sensors that continuously monitor multiple biomarkers. The core technology has implications for biomedical research, water quality management and metabolic monitoring, among others. Prashant Tathireddy talked about the technology works at the 2014 BIO International Convention.

Clearing feeding tubes faster – Biotech’s future

submitted by: nsf

Feeding tubes often become clogged with medication and food, depriving patients of nutrition. NSF-funded small business Actuated Medical has invented an FDA-approved device that clears clogs quickly and cleanly. Roger Bagwell demonstrated how the device works at the 2014 BIO International Convention.

Cognitive Heart Failure explained via 3D Animation

submitted by: Scientific Animations

CHF or Congestive Heart Failure, a condition on continuos rise explained - Are lifestyle changes responsible for increase in cases of CHF? What are the main causes? Economic impact on health system? Innovations in diagnosing and treating CHF?
Medical Industry Trends for CHF

Microbial signature profiles of periodontally healthy and diseased patients

submitted by: apcolombo
Aim: To determine microbial profiles that discriminate periodontal health from different forms of periodontal diseases. Methods: Subgingival biofilm was obtained from patients with periodontal health (27), gingivitis (11), chronic periodontitis (35) and aggressive periodontitis (24), and analysed for the presence of >250 species/phylotypes using HOMIM. Microbial differences among groups were examined by Mann–Whitney U-test. Regression analyses were performed to determine microbial...
Authors: Talita Lourenço, Debora Heller, Carina Silva-Boghossian, Sean Cotton, Bruce Paster, Ana Paula Colombo

Breakthrough Therapies for Idiopathic Pulmonary Fibrosis

submitted by: mcgheek

Timothy P.M. Whelan, M.D., Medical Director of the Lung Transplant Program at the Medical University of South Carolina, discusses promising clinical trial results of new agents (pirfenidone, nintedanib) for the treatment of idiopathic pulmonary fibrosis (IPF). To date, only supportive care and transplant (for eligible patients) have been available to IPF patients, but these new trial results could lead to FDA approval of the first drugs for IPF.